PL5230B1 - A method of producing a therapeutic agent to induce the renewal and synthesis process in the body. - Google Patents
A method of producing a therapeutic agent to induce the renewal and synthesis process in the body. Download PDFInfo
- Publication number
- PL5230B1 PL5230B1 PL5230A PL523025A PL5230B1 PL 5230 B1 PL5230 B1 PL 5230B1 PL 5230 A PL5230 A PL 5230A PL 523025 A PL523025 A PL 523025A PL 5230 B1 PL5230 B1 PL 5230B1
- Authority
- PL
- Poland
- Prior art keywords
- producing
- therapeutic agent
- synthesis process
- induce
- electrolytes
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 7
- 230000015572 biosynthetic process Effects 0.000 title claims description 3
- 239000003814 drug Substances 0.000 title claims description 3
- 238000003786 synthesis reaction Methods 0.000 title claims description 3
- 229940124597 therapeutic agent Drugs 0.000 title claims description 3
- 239000000787 lecithin Substances 0.000 claims description 7
- 229940067606 lecithin Drugs 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 239000003792 electrolyte Substances 0.000 claims description 6
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 5
- 235000010445 lecithin Nutrition 0.000 claims description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- 210000003372 endocrine gland Anatomy 0.000 claims description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- 230000008929 regeneration Effects 0.000 claims description 2
- 238000011069 regeneration method Methods 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 239000000284 extract Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- -1 thyroidin Chemical compound 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Description
» Wynalazek niniejszy dotyczy sposobu wytwarzania leczniczego srodka, powodu¬ jacego wzmozenie we krwi ilosci czerwo¬ nych loiailek, a wiec (przeznaczonego do ule¬ czania niekrwistosci i wogóle do wywolania w organizmie objawów odnowienia i synte¬ zy, wystepuj ajcych w znacznym stopniu.Wynalazek ten polega na dodawaniu do •wadtoej glicerynowo-lecytynowej emulsji, po dokladnem wymieszaniu, nieznacznej i- losci elektrolitów, jak np. chlorku sodo¬ wego, chlorku poitasoweigo, chlorku waipnio- wego i dwuweglanu sodowego.Podczas gdy mieszanina lecytyny z gli* ceryna po irozipusizczeniiiu jej w trzykrotnej ilosci wody wytwamza plyn iSyropowy, 4@- datek do tej mieszaniny nieznacznej ilosci elektrolitów wywoluje w niej wielkie za¬ burzenie, gdyz napiecie powierzchniowe i klejkowatosci mieszaniny zmniejszaja sie wileoefj niz dwiukrotnie, pnzez co ge¬ stosc mieszaniny zbliza sie do gestosci wo¬ dy tak, iz plyn moze byc latwo wstrzyki¬ wanym.Stwierdzono, ze po zastrzyknieciu pod- skórnem lub dozylnem wodnej glicerynowo- lecytynowej emulsji z nieznaczna domie¬ szka elektrolitów, daje sie w krótkim czasie zauwazyc w organizmie znaczny przyrost wai^i, co isie tlumaczy zwieikszemiem ilosci tluszczu i ibiallka W isurowitey.Równiez uijawnia) sie wydatna dlziiaiail-nosc organstyr tworzacych krew, np. po za- strzykiwaniach do zyl nastepuje znaczne wzmozenie sie ilosci czerwonych cialek we krwi.Dzieki szczególnej wlasciwosci miesza¬ niny wprowadza sie do organizmu lecytyne bez wywolania objawów zatrucia, które zwykle towarzysza przebiegowi odbudowy lecytyny we krwi. Spostrzezono np*, ze przy powtórnem zastrzykiwaniu wzmozenie sie ilosci czerwonych cialek krwi, docho¬ dzace do 60 — 100%, ustala sie pp pew¬ nym czasokresie, wzglednie po wprowadze¬ niu do organizmu oznaczonej ilosci zastrzy- kiwan. Np. u królika spostrzega sie po za- strzykiwaniaGh przyrost na wadze, wyno¬ szacy 50 — 60%, pozostajacy po ukoncze¬ niu zabiegów zastrzykowych.Równy przyrost wagi zostal stwierdzo¬ ny przy zastrzykiwaniach tego rodzaju u innych badanych zwierzat.Ilosc dodawanych elektrolitów i wza¬ jemny stosunek ich skladowych czesci daja sie ustalac kazdorazowo podlug pozadane¬ go stopnia oddzialywania zastrzykiwanego srodka.Pitzyklad. 1 czeisc wagowa ovo-leieytyny i 10 cz. wag. wody emulguje sie na cieplo, nastepnie mieszajac wprowadza sie do tej emulsji 2 cz. wag. gliceryny i 0,06 cz. wag. elektrolitycznej domieszki, skladajacej sie z chlorku sodowego, chlorku potasowego i chlorku wapmioweigo, dtodaijafc p^zytem bar¬ dzo nieznaczna ilosc kwasnego weglanu so¬ dowego i sody. Do zastrzykiwan podskór¬ nych zaleca sie dodawanie odrobiny chlor¬ ku magnezowego.Dla zmniejszenia bólu przy zastrzyki¬ waniach emuilsija lecytyny, gliicea-yny i elek- tnolitów moze byc /zimiesizaina z dowiolnemii] ilosciami insuliny, tyroidyny, adrenaliny, ovaryny i t. p. wyciagów z gruczolów wy¬ dzielania wewnetrznego i wstrzykiwana do organizmu. PLThe present invention relates to a method of producing a therapeutic agent which increases the amount of red blood in the blood, and thus (is intended to treat anemia and, in general, to induce regeneration and synthesis symptoms in the body, occurring to a large extent. this consists in adding a slight amount of electrolytes, such as sodium chloride, post-potassium chloride, sodium chloride and sodium bicarbonate to the defective glycerin-lecithin emulsion, after thorough mixing, while a mixture of lecithin with glycerin is mixed with cerine. and the addition of a small amount of electrolytes to this mixture causes a great disturbance in it, because the surface tension and viscosity of the mixture decrease by more than twice, and then the mixture is densely adjusted to the density of the mixture. water so that the liquid can be easily injected. It has been found that after injection under the skin or Due to the presence of a water-based glycerin-lecithin emulsion with a slight admixture of electrolytes, a significant increase in weight can be noticed in the body in a short time, which is explained by the increased amount of fat and the ibiallite W isuritey. For example, after injections into the veins, there is a significant increase in the amount of red cells in the blood. Due to the special properties of the mixture, lecithin is introduced into the body without causing the symptoms of intoxication that usually accompanies the recovery of lecithin in the blood. For example, it has been noticed that during repeated injections, the increase in the number of red blood cells, up to 60-100%, is determined by a pp over a certain period of time, or after a given number of injections have been introduced into the body. For example, after injecting a rabbit, a weight gain of 50-60% is observed after injection of the rabbit. Equal weight gain has been found with this type of injection in other test animals. Amount of electrolytes and the mutual ratio of their constituent parts can be determined in each case according to the desired degree of interaction of the injected agent. 1 part by weight of ovo-leieithin and 10 parts by weight wt. of water is emulsified while warm, then, while stirring, 2 parts of it are added to the emulsion. wt. glycerin and 0.06 parts wt. an electrolytic admixture consisting of sodium chloride, potassium chloride and calcium chloride, and a very small amount of acid sodium carbonate and soda was added to the plate. For subcutaneous injections, it is recommended to add a little magnesium chloride. To reduce pain when injecting emuilsija lecithin, gliicea-yin and electnolytes, it can be / zimiesizaine with additional amounts of insulin, thyroidin, adrenaline, ovarine with tp. endocrine glands and injected into the body. PL
Claims (3)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL5230B1 true PL5230B1 (en) | 1926-08-31 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL5230B1 (en) | A method of producing a therapeutic agent to induce the renewal and synthesis process in the body. | |
| EP0531391A1 (en) | Hydrogen peroxide preparations | |
| US1465530A (en) | Bath salts | |
| DE2327181A1 (en) | DISINFECTANT | |
| US1791878A (en) | Water-oil emulsion and suspension for medical purposes and process for manufacturing the same | |
| DE554349C (en) | Process for the production of foams | |
| SU7443A1 (en) | Method of making and using lecithin preparation for subcutaneous and intravenous infusions | |
| CH620124A5 (en) | Magnesium chloride tablets and process for their production | |
| DE635870C (en) | Process for the production of chlorinated rubber | |
| DE893703C (en) | Process for the production of alkali-free, ointment-like water-in-oil emulsions | |
| DE2200069C3 (en) | Process for the production of foam concrete | |
| JPH0499716A (en) | W/o/w type complex emulsion for injection and production thereof | |
| AT111858B (en) | Process for the preparation of artificial rubber. | |
| JPS6014933A (en) | Method for producing oil-in-water emulsion | |
| DE630344C (en) | Process for making anhydrous toothpastes | |
| DE632139C (en) | For the production of bathing, washing or skin care waters used capsule | |
| DE499078C (en) | Process for converting salt brines into a therapeutically effective paste or cream form | |
| CN107260598A (en) | One kind is refreshed oneself the spraying of U.S. face | |
| DE875777C (en) | Process for the use of emulsions as punching, pressing and molding oils in the ceramic industry | |
| DE1617202B1 (en) | Foaming agents in a process for making the same | |
| AT142709B (en) | Process for the preparation of an agent for regulating the acidity of gastric juice. | |
| US1742409A (en) | Agar compound | |
| US1707597A (en) | Fire-extinguishing compound | |
| SU1666112A1 (en) | Method of cream preparation for dry face skin | |
| DE1617202C (en) | Foaming agent and method of making the same |